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Immune evasion strategies of the herpesviruses 
Ian A  York 
All viruses can deal with the immune response to some 
extent, and herpesviruses are exceptionally sophisticated 
in this ability. Recent work has uncovered some of the 
mechanisms by which herpesviruses subvert the antigen- 
presentation systems of their host cells. 
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Every animal virus must be able to overcome its host’s 
immune response to some extent. Some viruses ‘hit and 
run’, completing replication before the immune response 
is fully aroused, and others escape the consequences of 
the responses they generate by altering their surface anti- 
gens. But there are much more sophisticated ways for 
viruses to avoid, evade, or modify the immune system. 
Identification of these strategies can help us to decipher 
the origins of viral pathogenesis; it can also help us to 
understand antiviral immunity, by identifying the aspects 
of the immune system the virus deems most dangerous, 
and the elements of the immune system that evolved to 
overcome or circumvent the evasion systems. Further- 
more, since many viral molecules seem to efficiently block 
components of the immune response while having little 
effect on other systems, it may be possible to take thera- 
peutic and experimental advantage of millions of years of 
viral evolution. 
To be successful, viruses must deal with both the humoral 
(B lymphocyte and antibody) and cellular (T lymphocyte) 
branches of the immune system. The humoral system is 
primarily useful in attacking extracellular pathogens. 
Intracellular pathogens such as viruses are vulnerable to 
the humoral system during the initial entry into the body 
and while spreading from one cell to another, but are more 
effectively controlled by the cell-mediated immune 
system, in particular cytotoxic T lymphocytes (CTL). 
CTL recognize virus-infected cells through interactions of 
their T cell receptor and CD8 surface molecule with class 
I major histocompatibility complexes (MHC class I) on 
the infected cell’s surface. 
The MHC class I complex consists of a polymorphic trans- 
membrane heavy chain (HC) associated with a non-poly- 
morphic light chain (~z-microglobulin) and a pepcide 
derived from proteolysis of cytoplasmic proteins. By trans- 
ferring these peptides from the cytoplasm to the cell 
surface, the MHC class I antigen presentation system 
(reviewed in [1,2]; see Fig. 1) provides CTL with a means 
of inspecting the intracellular environment. 
The production and delivery of potentially antigenic pep- 
tides has several stages. Proteins are degraded in the cyto- 
plasm, mainly by the proteasome, and the peptides thus 
produced bind to the cytoplasmic face of TAP (transporter 
associated with antigen processing), a heterodimer of 
transporter proteins of the ATP-binding cassette family 
(reviewed in [3]). TAP prefers to bind peptides of 
between 8 and 16 amino acids in length, but is quite 
promiscuous regarding peptide sequence. After binding 
peptides, TAP transports them across the endoplasmic 
reticulum (ER) membrane. In the ER lumen, the interac- 
tion of peptides with newly synthesized MHC I molecules 
allows the complex of MHC I and peptide to exit the ER. 
If the peptide was originally derived from a normal cellu- 
lar protein, the phenomenon of self-tolerance [4] ensures 
that CTLs ignore it. If the peptide was derived from a 
viral protein, however, CTLs can recognize the combina- 
tion of foreign peptide and MHC I at the cell surface and 
are triggered to lyse the target cell, thus blocking further 
viral replication. Not surprisingly, many viruses have 
evolved mechanisms for evading the CTL recognition and 
clearance system. 
Here I focus on the immune-evasion strategies of three 
members of the herpesviridae. These are large viruses, 
with genomes ranging from 100 kDa to 250 kDa or more, 
which characteristically infect their hosts for life. Many of 
them can spread from cell KO cell without entering the 
extracellular environment, so that the humoral immune 
system has little opportunity to clear an infection. There 
are scores of human and animal herpesviruses (reviewed 
in [S]); here I will touch on some of the mechanisms used 
to evade CTL by three ubiquitous human herpesviruses: 
the closely related herpes simplex viruses (HSV) types 1 
and 2, and human cytomegalovirus (HCMV). 
Herpes simplex virus 
HSV types 1 and 2 replicate in superficial tissues, typically 
the lip or genitals. After the initial infection, they establish 
a latent infection in neurons; as few if any viral proteins are 
expressed during latency and neurons are relatively shel- 
tered from the immune system, latent HSV is unlikely to 
be eliminated. The viruses can reactivate from latency and 
reinfect superficial tissues in spite of the immune re- 
sponse, which is at most moderately suppressed. Although 
the HSVs express a number of gene products involved in 
evasion of the humoral immune response, these are most 
likely to be important in the initial infection before the 
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Figure 1 
The class I major histocompatibility complex 
antigen presentation pathway. The class I 
MHC is composed of a transmembrane 
heavy chain (1) bound to a soluble protein, 
f3,-microglobulin. These proteins are co- 
translationally translocated across the ER 
membrane, and bind in the lumen of the ER 
(2). Cytoplasmic proteins (3) are degraded 
by the proteasome (4) to produce peptides 
(5). These peptides bind to the cytoplasmic 
face of TAP (6) which then transfers the 
peptides into the lumen of the ER (7). In the 
ER, peptides bind to newly synthesized class 
I MHC to form a trimeric complex of heavy 
chain, f3,-microglobulin and peptide (8). This 
complex exits the ER, passes through the 
Golgi complex (9) and reaches the cell 
surface (lo), where it can be surveyed by 
cytotoxic T  lymphocytes. 
virus first enters cells, rather than in the ongoing infection 
(reviewed in [6]). 
The cellular immune response to HSV in humans is 
unusual in that CD8+ CTL specific for HSV are relatively 
rare and often recognize peptides derived from virion 
structural proteins brought into the cell in the process of 
viral invasion, instead of the much more abundant prod- 
ucts of de novo viral protein synthesis [7]. These observa- 
tions suggest that the HSVs may actively perturb the 
MHC class I/CTL system. Indeed, MHC class I in HSV- 
infected human fibroblasts is misfolded and retained with- 
in the ER [8,9], because peptide is not supplied to the 
nascent MHC class I complex within the ER. This block- 
ade of peptide supply is mediated by a viral protein, 
ICP47 [9], a small cytoplasmic protein that prevents TAP 
from transporting peptide into the ER lumen [lO,ll]. 
ICP47 is a member of the immediate-early class of viral 
genes, and is expressed very shortly after viral infection; 
thus, antigen presentation is effectively blocked as soon as 
viral genes are expressed. This means that CTL are limited 
to recognition of the viral proteins present in the cell before 
ICP47 expression (mainly those present in the infecting 
virion particle), accounting for the scarcity of human CTL 
directed against non-structural HSV proteins (Fig. 2). 
The mechanism of ICP47’s action has recently been par- 
tially elucidated. ICP47 binds with high affinity to human 
TAP, inhibiting peptides from binding to the transporter 
[l&13] and therefore preventing peptide translocation. 
The inhibition of peptide binding is competitive, suggest- 
ing that ICP47 binds to the peptide-binding site of TAP, 
but ICP47 binding is clearly not identical to peptide bind- 
ing. ICP47 is 88 amino acids in length (87 amino acids in 
HSV-2) and peptides longer than about 16 amino acids 
seem to bind TAP with low affinity [14], yet ICP47 binds 
TAP with at least lo-fold higher affinity than do peptides 
and, unlike peptides, is not transported across the ER 
membrane [l&13]. Presumably ICP47 contacts TAP resi- 
dues adjacent to the peptide-binding site as well as those 
of the peptide-binding site itself. 
Human cytomegalovirus 
HCMV, like HSV, establishes a lifelong infection even in 
immune-competent people, but rarely causes disease except 
in those who are immunosuppressed. HCMV is faced with 
an even more challenging immunological environment than 
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Figure 2 
Effect of HSV on antigen presentation. In 
cells infected with HSV, the cytoplasmic 
protein ICP47 (1) binds to the cytoplasmic 
face of TAP (2) blocking the peptide-binding 
site and preventing peptides from entering 
the ER lumen. Because the MHC class I 
complex (3) cannot exit the ER until it has 
associated with peptide, it is retained in the 
ER in HSV-infected cells and no newly 
formed MHC class I (which could carry viral 
peptides) reaches the cell surface. Only 
those MHC class I complexes formed prior to 
viral infection (4) are on the cell surface. 
is HSV. It infects a wide range of cell types, including such 
efficient antigen-presenting cells as macrophages and lym- 
phocytes as well as epithelial cells and fibroblasts, and 
takes considerably longer than HSV to replicate, so 
that infected cells are vulnerable to lysis by CTL for a 
longer time. 
A partial explanation for HCMV’s immunity to the 
immune system lies in its ability to inhibit CTL recogni- 
tion. Fibroblasts infected with HCMV have low cell- 
surface MHC class I [l&16], due to rapid degradation of 
the MHC class I heavy chain [17]. HC is normally quite 
stable, with a half-life measured in hours, but in HCMV- 
infected cells its half-life can be as short as one minute. 
Cells infected with a mutant HCMV lacking nine genes 
failed to induce HC degradation, suggesting that at least 
one of those genes is involved in the process, and a cell 
line transfected with one of the genes, USll, showed 
rapid degradation of heavy chain [ 181. 
The degradation of HC induced by US11 can be blocked 
by inhibitors of the proteasome, suggesting that degrada- 
tion might occur in the cytoplasm. Subcellular fractionation 
in the presence of proteasome inhibitors confirmed that 
WC was present in the cytoplasm and not the ER in US1 l- 
expressing cells. But it appeared to have been N-glycosy- 
lated and then deglycosylated, suggesting that it had 
temporarily reached the ER lumen before entering the 
cytoplasm [19]. It seems that, in the presence of US1 1, the 
HC, despite its transmembrane anchor region, falls or is 
pushed out of the ER membrane to become a soluble cyto- 
plasmic protein (Fig. 3). Not surprisingly, in this alien envi- 
ronment, where the HC is presumably misfolded, it is 
rapidly degraded. 
The mechanism by which US11 causes HC to enter the 
cytoplasm is not yet known. Proteins destined for the ER 
are co-translationally translocated across the ER mem- 
brane in a proteinaceous channel; transmembrane proteins 
are believed to move laterally out of this channel to insert 
their transmembrane anchor into the ER membrane 
(reviewed in [ZO]). HC seems to be displaced to the cyto- 
plasm as fast as it is synthesized [19], suggesting that it 
may never have the chance to insert itself into the mem- 
brane. US11 may be forcing HC into a non-physiological 
route, or, perhaps more likely, it may be taking advantage 
of a normal pathway; in either case, this represents a previ- 
ously unknown route from the ER to the cytoplasm. 
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Figure 3 
Effect of HCMV on antigen presentation. In 
ceils infected with HCMV, the viral protein 
US1 1 (1) induces the MHC class I heavy 
chain to be released from the ER membrane 
and enter the cytoplasm (21, where it is 
rapidly degraded by the proteasome (3). 
MHC class I at the cell surface is lost due to 
normal turnover. As NK cells normally lyse 
cells with low cell-surface MHC class I, this 
would eventually cause these cells to be 
susceptible to NK lysis. A  second viral 
protein, UL18 (4) has homology to the MHC 
class I heavy chain, binds f3s-microglobulin 
and peptide, and reaches the cell surface 
(5); this protein may act as camouflage, 
inhibiting NK cells from lysing the infected 
cell, yet failing to stimulate CTL. 
Multiple lines of defense 
Surprisingly, HCMV mutants lacking US11 still prevent 
the surface expression of MHC class I [18]. Another gene 
product, USZ, is also capable of causing rapid degradation 
of the heavy chain, perhaps by a different mechanism than 
that used by US11 (E. Wiertz, T Jones and H. Ploegh, 
unpublished data). Nor is this the limit of HCMV’s anti- 
CTL arsenal; US3 binds to MHC class I and retains it in 
the ER, and at least one other gene independently pre- 
vents MHC class I surface expression (K. Ahn, A. Angulo, 
P. Ghazal, PA. Peterson, Y. Yang and K. Friih, unpublished 
data). Why does HCMV need so many proteins to inhibit 
MHC class I antigen presentation, when US11 seems to 
be effective alone? Similarly, several observations suggest 
that ICP47 is the only HSV protein affecting MHC class I 
antigen presentation [9-111; if HCMV requires four or 
more proteins to adequately defend itself against CTL, 
why does HSV only need one? 
Part of the reason may be that the different proteins are 
active at different phases of the viral life cycle. US11 
expression begins within a few hours of infection and 
decreases after two or three days [‘Zl], well before HCMV 
replication is complete. Other gene products may be 
effective later than USll, while US3, an immediate-early 
gene, is expressed earlier than US1 1. ICP47, in contrast, is 
probably present for almost all of the two-day HSV repli- 
cation cycle. Another possible explanation is that HCMV 
has to contend with antigen presentation in more cell 
types than does HSV: although HSV does infect several 
cell types, the main site of HSV latency is neurons, which 
normally express little or no MHC class I. The HCMV 
strategy of infiltration into the opposing corps, infecting 
so-called ‘professional’ antigen-presenting cells like 
macrophages, may require a more profound block than 
HSV’s approach of repeated raids from ambush. 
The long infectious cycle of HCMV raises a problem for 
the virus that HSV may not have to deal with. Natural 
killer (NK) cells are lytic lymphocytes which, instead of 
recognizing peptide in the presence of MHC class I, pref- 
erentially lyse cells with low MHC class I expression; their 
lytic ability is inhibited by MHC class I molecules 
(reviewed in [Z&23]). As cell-surface MHC class I mole- 
cules can have a half-life of 12 h or more, the HSV replica- 
tion cycle can be completed before the level of MHC class 
I molecules on the cell surface is significantly reduced. 
HCMV-infected cells, on the other hand, will have low 
cell-surface MHC class I levels well before new infectious 
HCMV particles are formed. Intriguingly, HCMV ex- 
presses a protein, UL18, which not only shows sequence 
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similarity to the MHC class I heavy chain, but also binds 
&-microglobulin and peptide [24]. Fahnestock and co- 
workers suggest that this protein may camouflage infected 
cells, inhibiting NK cells without stimulating CD8+ CTL. 
HLA class I molecules are not transported to the cell surface in cells 
infected with herpes simplex virus types 1 and 2. J. /mmuno/. 152, 
2736-2741, 
Significance and implications 
Although HSV and HCMV normally block CTL recogni- 
tion of infected cells, severe herpesvirus disease is rare in 
people with normal immune systems. Does this mean that 
CTL are not important in controlling these viral infections? 
Not necessarily - although human CD8+ CTL specific for 
HCMV are mainly directed against virion structural pro- 
teins, they are readily detectable and are associated with 
protection against infection [ZS]. HSV-specific CD8+ CTL 
are relatively rare, though still detectable, and their impor- 
tance is less clear. Other components of the immune 
system, such as NK cells or CD4+ CTL, may be particularly 
important in controlling herpesvirus infections, but the 
species specificity of the viruses and their immune evasion 
proteins (neither ICP47 [8-111 nor US11 [E. Wiertz, T. 
Jones and H. Ploegh, unpublished data] are fully effective 
in mouse cells) make in ZX& experiments difficult. 
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This review has only dealt with three of the eight human 19. Wiertz, E.J.H.J., Jones, T.R., Sun, L., Bogyo, M., Geuze, H.J. & Ploegh, 
herpesviruses, and a few of the tactics they use to evade H.L. (1996). The human cytomegalovirus US1 1 gene product 
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